

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Negishi et al.

Application No. 10/505,183

FILED VIA EFS

Filed: August 18, 2004

Confirmation No. 2375

For: MUTATED CONSTITUTIVELY ACTIVE
NUCLEAR ORPHAN RECEPTOR

Examiner: Shulamith H. Shafer, Ph.D.

Art Unit: 1647

Attorney Reference No. 4239-64458-02

SUBMITTED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith is one English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent. This Supplemental Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

The Commissioner is authorized to charge the \$180.00 fee required in connection with filing this IDS, and/or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

/JODI L. CONNOLLY/

By _____
Jodi L. Connolly, Ph.D.
Registration No. 54,044

cc: Docketing